Literature DB >> 21762916

Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?

Olivier S Descamps1, Johan De Sutter, Michel Guillaume, Luc Missault.   

Abstract

The evidence of the different concepts underlying the interplay between cholesterol absorption and synthesis in the context of statin and ezetimibe treatment were reviewed in the light of the eight major trials where cholesterol absorption and synthesis were analyzed on a large scale using the plasma levels of precursors of cholesterol and plant sterols. The only concept supported in all studies is a significant and consistent increase of cholesterol absorption with statin (correlated with the inhibition of synthesis) and of cholesterol synthesis with ezetimibe, whereas in combination, statin and ezetimibe reduce both cholesterol synthesis and absorption. In contrast, most of the other concepts failed to be clearly proven. At baseline, the inverse relationship between cholesterol absorption and synthesis (only examined in two studies) was found to be weak. On statin treatment, four studies showed that the changes in cholesterol synthesis and absorption, contributed less than 9% to the variability in cholesterol response to statin therapy. It has not been consistently demonstrated that good absorbers/bad synthesizers are bad responders to statin (6 studies) and good responders for ezetimibe (3 studies). There is also no clear inverse correlation between LDL reduction on statin treatment and that on ezetimibe treatment. Finally, the original idea from the first pioneer study of Miettinen et al. that, the higher the baseline intestinal ability to absorb cholesterol, the lower the benefit on the clinical cardiovascular outcomes was not reproduced in the PROSPER study. In conclusion, with the exception of a reverse effect of statin and ezetimibe on absorption and synthesis, most ideas supporting the interplay between cholesterol absorption and synthesis lacked consistency between studies. At present, the use of the plasma levels of plant sterols and cholesterol precursors as markers of cholesterol absorption and synthesis is far too limited to definitively solve these questions.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762916     DOI: 10.1016/j.atherosclerosis.2011.06.010

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations.

Authors:  Niek C A van de Pas; Johan A C Rullmann; Ruud A Woutersen; Ben van Ommen; Ivonne M C M Rietjens; Albert A de Graaf
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-09       Impact factor: 2.745

2.  Effect of evolocumab on cholesterol synthesis and absorption.

Authors:  Matthew Peach; Ren Xu; Dan Fitzpatrick; Lisa Hamilton; Ransi Somaratne; Robert Scott; Scott M Wasserman; C Stephen Djedjos
Journal:  J Lipid Res       Date:  2016-10-05       Impact factor: 5.922

3.  Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.

Authors:  Jen-Chieh Chuang; Mark A Valasek; Adam M Lopez; Kenneth S Posey; Joyce J Repa; Stephen D Turley
Journal:  Biochem Pharmacol       Date:  2014-01-31       Impact factor: 5.858

4.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

5.  Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease.

Authors:  Yue Qi; Jing Liu; Changsheng Ma; Wei Wang; Xiaohui Liu; Miao Wang; Qiang Lv; Jiayi Sun; Jun Liu; Yan Li; Dong Zhao
Journal:  J Lipid Res       Date:  2013-08-20       Impact factor: 5.922

6.  Plasma plant sterols serve as poor markers of cholesterol absorption in man.

Authors:  Lily Jakulj; Hussein Mohammed; Theo H van Dijk; Theo Boer; Scott Turner; Albert K Groen; Maud N Vissers; Erik S G Stroes
Journal:  J Lipid Res       Date:  2012-11-25       Impact factor: 5.922

7.  Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.

Authors:  Livia Pisciotta; Antonella Bellocchio; Stefano Bertolini
Journal:  Lipids Health Dis       Date:  2012-09-22       Impact factor: 3.876

Review 8.  Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy.

Authors:  Olov Wiklund; Carlo Pirazzi; Stefano Romeo
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

Review 9.  The Interpretation of Cholesterol Balance Derived Synthesis Data and Surrogate Noncholesterol Plasma Markers for Cholesterol Synthesis under Lipid Lowering Therapies.

Authors:  Frans Stellaard; Dieter Lütjohann
Journal:  Cholesterol       Date:  2017-02-22

10.  LDL-Cholesterol-Lowering Therapy.

Authors:  Angela Pirillo; Giuseppe D Norata; Alberico L Catapano
Journal:  Handb Exp Pharmacol       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.